B Cell Lymphoma Treatment Options

When lymphoma is discovered to affect the B cells, prognosis is generally pretty good almost regardless of subtype. It will almost surely be better than the prognosis for T-cell lymphomas, in large part because B cell lymphomas account for as much as 85% of all Non-Hodgkin's lymphomas, so inevitably more research has gone into these diseases than into the T-cell lymphomas.


Tumor Grades

Perhaps the most important determination is whether the cancer is indolent (slow-growing) or aggressive. This determination is made by the pathologist who reviews slides from the patient's biopsy.

Treatment Options

Watch & Wait

  • No treatments are prescribed
  • Patient and his/her doctor simply watch and wait for symptoms to appear
  • Only used against indolent or slow-growing lymphomas


  • Used against both indolent and aggressive B cell lymphomas
  • Typically used following chemotherapy and against a bulky tumor mass (if the patient has one) in order to make sure all the cancer cells in the patient's body are killed


  • Most commonly applied B cell lymphoma treatment (including B cell lymphomas that are indolent as well as aggressive)

Although there are several chemotherapeutic drugs used against lymphomas, the most common are cyclophosphamide, doxorubicin, vincristine, prednisone and Rituxan When administered together, this is known as R-CHOP combination chemotherapy, the most commonly used chemotherapy treatment in B cell lymphomas.


  • Generally refers to one drug: Rituxan, a monoclonal antibody that seeks out only certain cells within the body and kills them
  • Used both as a single-agent and in combination chemotherapy
  • As a single-agent, Rituxan is often used in what's called maintenance therapy for patients with indolent lymphomas

Radioimmunotherapy (RIT)

This is an emerging treatment option for the indolent subgroup of lymphomas, especially follicular lymphoma.

Two RIT options are currently in use:

Although there are differences between these two therapies, both function the same way: They take a monoclonal antibody and attach to it a radioactive isotope, which is injected into the body. The monoclonal antibody seeks out certain lymphocytes and attaches on to them, then delivers the radioactive payload.

These therapies are administered like chemotherapy (through infusions) but kill cancer cells like radiation.

Hematopoietic Stem Cell Transplantation

  • Also referred to as bone marrow transplantation
  • Generally considered the last line of B cell lymphoma treatment against a particularly refractory B cell lymphoma because the procedure is difficult and potentially fatal

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...